Small Molecular TRAIL Inducer ONC201 Induces Death in Lung Cancer Cells: A Preclinical Study

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising anti-cancer agent due to its selective toxicity towards cancer cells.
• ONC201 is a novel small molecule designed to induce TRAIL expression and activate apoptosis pathways in cancer cells.

Purpose of the Study:

• To evaluate the anti-cancer efficacy of ONC201 in preclinical lung cancer models.
• To elucidate the molecular mechanisms underlying ONC201's anti-cancer activity.

Main Methods:

• Cytotoxicity and anti-proliferative assays were performed on established and primary human lung cancer cell lines, as well as normal lung epithelial cells.
• Apoptosis activation was assessed by measuring TRAIL/death receptor-5 (DR5) induction and caspase-8 activation.
• Signaling pathways (Akt-S6K1, Erk, Foxo3a) were analyzed.
• In vivo efficacy was evaluated using xenografted A549 tumors in SCID mice.

Main Results:

• ONC201 demonstrated significant cytotoxicity and anti-proliferative effects against lung cancer cells, with no observed toxicity in normal lung cells.
• ONC201 induced apoptosis via TRAIL/DR5 upregulation and caspase-8 activation, which was reversible with caspase-8 inhibition or TRAIL/DR5 knockdown.
• The drug inactivated Akt-S6K1 and Erk signaling pathways, leading to Foxo3a nuclear translocation.
• In vivo, ONC201 significantly inhibited A549 tumor growth in mice at well-tolerated doses, with similar molecular changes observed in tumor tissues.

Conclusions:

• ONC201 exhibits potent anti-lung cancer activity through the induction of apoptosis and inhibition of key oncogenic signaling pathways.
• Its selective toxicity and efficacy in preclinical models suggest ONC201 holds promise as a novel therapeutic agent for lung cancer.